弥漫性大B细胞淋巴瘤的整合基因组分析识别与双特异性抗体应答相关的免疫环境
该研究采用整合多组学方法分析多个大型独立数据集,将弥漫性大B细胞淋巴瘤(DLBCL)按细胞起源和免疫相关基因集表达评分分为4个免疫象限(IQ)。在复发/难治性DLBCL患者中,DLBCL-IQ分型与CD20×CD3双特异性抗体(BsAb)的临床获益显著相关(N=74),但与CD19靶向CAR T细胞治疗无关(斯坦福N=51;纪念斯隆凯特琳癌症中心N=69)。
要点
- DLBCL可分为ABC热、ABC冷、GCB热和GCB冷4个免疫象限。
- SOCS1功能缺失突变在GCB热型DLBCL中显著富集。
- DLBCL-IQ分型与CD20×CD3 BsAb临床获益显著相关,与CAR T细胞治疗无关。
核心结论
- DLBCL-IQ为理解DLBCL免疫景观提供了新框架,并提示内源性免疫环境对BsAb治疗结局的影响比CAR T细胞治疗更显著。
研究设计与样本
- 应用整合多组学方法分析多个大型独立数据集,以表征DLBCL免疫环境及其与肿瘤细胞内在基因组改变和治疗结局的关联。
主要发现
- 该方法将DLBCL有效分为4个免疫象限:ABC热、ABC冷、GCB热和GCB冷。
- 每个免疫象限中富集了特定的复发性基因组改变,提示淋巴瘤细胞内在改变对塑造独特DLBCL免疫环境有显著贡献。
- SOCS1功能缺失突变在GCB热型DLBCL中显著富集,识别出可能对免疫治疗具有内在易感性的炎症型DLBCL亚群。
- 在复发/难治性DLBCL患者中,DLBCL-IQ分型与CD20×CD3 BsAb的临床获益显著相关(N=74),但与CD19靶向CAR T细胞治疗无关(斯坦福N=51;纪念斯隆凯特琳癌症中心N=69)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Most patients with diffuse large B-cell lymphoma (DLBCL) treated with immunotherapies such as bispecific antibodies (BsAbs) or chimeric antigen receptor (CAR) T cells fail to achieve durable treatment responses, underscoring the need for a deeper understanding of mechanisms that regulate the immune environment and response to treatment. Here, an integrative multiomics approach was applied to multiple large independent data sets to characterize DLBCL immune environments and to define their association with tumor cell-intrinsic genomic alterations and outcomes to CD19-directed CAR T-cell and CD20 × CD3 BsAb therapies. This approach effectively segregated DLBCLs into 4 immune quadrants (IQs) defined by cell-of-origin and immune-related gene set expression scores. These quadrants consisted of activated B cell-like (ABC) hot, ABC cold, germinal center B cell-like (GCB) hot, and GCB cold DLBCLs. Recurrent genomic alterations were enriched in each IQ, suggesting that lymphoma cell-intrinsic alterations contribute significantly to orchestrating unique DLBCL immune environments. For instance, SOCS1 loss-of-function mutations were significantly enriched among GCB hot DLBCLs, identifying a putative subset of inflamed DLBCLs that may be inherently susceptible to immunotherapy. In patients with relapsed/refractory DLBCL, DLBCL-IQ assignment correlated significantly with clinical benefit with a CD20 × CD3 BsAb (N = 74), but not with CD19-directed CAR T cells (Stanford, N = 51; Memorial Sloan Kettering Cancer Center, N = 69). Thus, DLBCL-IQ provides a new framework to conceptualize the DLBCL immune landscape and suggests the endogenous immune environment has a more significant impact on outcomes to BsAb than CAR T-cell treatment.
引用
- Tumuluru S, Godfrey JK, Cooper A, et al. Integrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody response. Blood. 2025. PMID: 39869833. doi:10.1182/blood.2024025355
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。